Skip to main content
Top
Published in: BMC Geriatrics 1/2013

Open Access 01-12-2013 | Research article

Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS database

Authors: Joseph E Gaugler, Haya Ascher-Svanum, David L Roth, Tolulope Fafowora, Andrew Siderowf, Thomas G Beach

Published in: BMC Geriatrics | Issue 1/2013

Login to get access

Abstract

Background

This study compared individuals whose clinical diagnosis of Alzheimer’s disease (AD) matched or did not match neuropathologic results at autopsy on clinical and functional outcomes (cognitive impairment, functional status and neuropsychiatric symptoms). The study also assessed the extent of potentially inappropriate medication use (using potentially unnecessary medications or potentially inappropriate prescribing) among misdiagnosed patients.

Methods

Longitudinal data from the National Alzheimer’s Coordinating Center Uniform Data Set (NACC-UDS, 2005–2010) and corresponding NACC neuropathological data were utilized to compare 88 misdiagnosed and 438 accurately diagnosed patients.

Results

Following adjustment of sociodemographic characteristics, the misdiagnosed were found to have less severe cognitive and functional impairment. However, after statistical adjustment for sociodemographics, dementia severity level, time since onset of cognitive decline and probable AD diagnosis at baseline, the groups significantly differed on only one outcome: the misdiagnosed were less likely to be depressed/dysphoric. Among the misdiagnosed, 18.18% were treated with potentially inappropriate medication. An additional analysis noted this rate could be as high as 67.10%.

Conclusions

Findings highlight the importance of making an accurate AD diagnosis to help reduce unnecessary treatment and increase appropriate therapy. Additional research is needed to demonstrate the link between potentially inappropriate treatment and adverse health outcomes in misdiagnosed AD patients.
Literature
1.
go back to reference Grand JH, Caspar S, Macdonald SW: Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc. 2011, 4: 125-147.PubMedPubMedCentral Grand JH, Caspar S, Macdonald SW: Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc. 2011, 4: 125-147.PubMedPubMedCentral
2.
go back to reference Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ: National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012, 8 (1): 1-13. 10.1016/j.jalz.2011.10.007.CrossRefPubMedPubMedCentral Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ: National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012, 8 (1): 1-13. 10.1016/j.jalz.2011.10.007.CrossRefPubMedPubMedCentral
3.
go back to reference McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7 (3): 263-269. 10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011, 7 (3): 263-269. 10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral
4.
go back to reference Beach TG, Monsell SE, Phillips LE, Kukull W: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012, 71 (4): 266-273. 10.1097/NEN.0b013e31824b211b.CrossRefPubMedPubMedCentral Beach TG, Monsell SE, Phillips LE, Kukull W: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012, 71 (4): 266-273. 10.1097/NEN.0b013e31824b211b.CrossRefPubMedPubMedCentral
5.
go back to reference Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB: Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc. 1999, 47 (5): 564-569.CrossRefPubMed Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, Bowen J, Teri L, Thompson J, Peskind ER, Raskind M, Larson EB: Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc. 1999, 47 (5): 564-569.CrossRefPubMed
6.
go back to reference Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s disease centers consortium on apolipoprotein E and Alzheimer’s disease. N Engl J Med. 1998, 338 (8): 506-511. 10.1056/NEJM199802193380804.CrossRefPubMed Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s disease centers consortium on apolipoprotein E and Alzheimer’s disease. N Engl J Med. 1998, 338 (8): 506-511. 10.1056/NEJM199802193380804.CrossRefPubMed
7.
go back to reference Ranginwala NA, Hynan LS, Weiner MF, White CL: Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry. 2008, 16( (5): 384-388.CrossRef Ranginwala NA, Hynan LS, Weiner MF, White CL: Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry. 2008, 16( (5): 384-388.CrossRef
8.
go back to reference Pearl GS: Diagnosis of Alzheimer’s disease in a community hospital-based brain bank program. South Med J. 1997, 90 (7): 720-722. 10.1097/00007611-199707000-00013.CrossRefPubMed Pearl GS: Diagnosis of Alzheimer’s disease in a community hospital-based brain bank program. South Med J. 1997, 90 (7): 720-722. 10.1097/00007611-199707000-00013.CrossRefPubMed
9.
go back to reference Klatka LA, Schiffer RB, Powers JM, Kazee AM: Incorrect diagnosis of Alzheimer’s disease. A clinicopathologic study. Arch Neurol. 1996, 53 (1): 35-42. 10.1001/archneur.1996.00550010045015.CrossRefPubMed Klatka LA, Schiffer RB, Powers JM, Kazee AM: Incorrect diagnosis of Alzheimer’s disease. A clinicopathologic study. Arch Neurol. 1996, 53 (1): 35-42. 10.1001/archneur.1996.00550010045015.CrossRefPubMed
10.
go back to reference Piccini C, Bracco L, Amaducci L: Treatable and reversible dementias: an update. J Neurol Sci. 1998, 153 (2): 172-181. 10.1016/S0022-510X(97)00289-X.CrossRefPubMed Piccini C, Bracco L, Amaducci L: Treatable and reversible dementias: an update. J Neurol Sci. 1998, 153 (2): 172-181. 10.1016/S0022-510X(97)00289-X.CrossRefPubMed
11.
go back to reference Hejl A, Hogh P, Waldemar G: Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry. 2002, 73 (4): 390-394. 10.1136/jnnp.73.4.390.CrossRefPubMedPubMedCentral Hejl A, Hogh P, Waldemar G: Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry. 2002, 73 (4): 390-394. 10.1136/jnnp.73.4.390.CrossRefPubMedPubMedCentral
12.
go back to reference Wang BW, Lu E, Mackenzie IR, Assaly M, Jacova C, Lee PE, Beattie BL, Hsiung GY: Multiple pathologies are common in Alzheimer patients in clinical trials. Can J Neurol Sci. 2012, 39 (5): 592-599.CrossRefPubMed Wang BW, Lu E, Mackenzie IR, Assaly M, Jacova C, Lee PE, Beattie BL, Hsiung GY: Multiple pathologies are common in Alzheimer patients in clinical trials. Can J Neurol Sci. 2012, 39 (5): 592-599.CrossRefPubMed
13.
go back to reference Gay BE, Taylor KI, Hohl U, Tolnay M, Staehelin HB: The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients. J Nutr Health Aging. 2008, 12 (2): 132-137. 10.1007/BF02982566.CrossRefPubMed Gay BE, Taylor KI, Hohl U, Tolnay M, Staehelin HB: The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients. J Nutr Health Aging. 2008, 12 (2): 132-137. 10.1007/BF02982566.CrossRefPubMed
14.
go back to reference Jellinger KA: Clinicopathological analysis of dementia disorders in the elderly–an update. J Alzheimers Dis. 2006, 9 (3 Suppl): 61-70.PubMed Jellinger KA: Clinicopathological analysis of dementia disorders in the elderly–an update. J Alzheimers Dis. 2006, 9 (3 Suppl): 61-70.PubMed
15.
go back to reference Brunnstrom H, Englund E: Clinicopathological concordance in dementia diagnostics. Am J Geriatr Psychiatry. 2009, 17 (8): 664-670. 10.1097/JGP.0b013e3181a6516e.CrossRefPubMed Brunnstrom H, Englund E: Clinicopathological concordance in dementia diagnostics. Am J Geriatr Psychiatry. 2009, 17 (8): 664-670. 10.1097/JGP.0b013e3181a6516e.CrossRefPubMed
16.
go back to reference Boxer AL, Boeve BF: Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007, 21 (4): S79-S87. 10.1097/WAD.0b013e31815c345e.CrossRefPubMed Boxer AL, Boeve BF: Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007, 21 (4): S79-S87. 10.1097/WAD.0b013e31815c345e.CrossRefPubMed
17.
go back to reference Irwin D, Lippa CF, Rosso A: Effects of prescribed medications on cognition and behavior in frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2010, 25 (7): 566-571. 10.1177/1533317510382285.CrossRefPubMed Irwin D, Lippa CF, Rosso A: Effects of prescribed medications on cognition and behavior in frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2010, 25 (7): 566-571. 10.1177/1533317510382285.CrossRefPubMed
18.
go back to reference Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B: Are amyotrophic lateral sclerosis patients cognitively normal?. Neurology. 2003, 60 (7): 1094-1097. 10.1212/01.WNL.0000055861.95202.8D.CrossRefPubMed Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B: Are amyotrophic lateral sclerosis patients cognitively normal?. Neurology. 2003, 60 (7): 1094-1097. 10.1212/01.WNL.0000055861.95202.8D.CrossRefPubMed
19.
go back to reference Lomen-Hoerth C, Anderson T, Miller B: The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002, 59 (7): 1077-1079. 10.1212/WNL.59.7.1077.CrossRefPubMed Lomen-Hoerth C, Anderson T, Miller B: The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002, 59 (7): 1077-1079. 10.1212/WNL.59.7.1077.CrossRefPubMed
20.
go back to reference Kerchner GA, Tartaglia MC, Boxer A: Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother. 2011, 11 (5): 709-717. 10.1586/ern.11.6.CrossRefPubMedPubMedCentral Kerchner GA, Tartaglia MC, Boxer A: Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Rev Neurother. 2011, 11 (5): 709-717. 10.1586/ern.11.6.CrossRefPubMedPubMedCentral
21.
go back to reference McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Machado JC, O’Brien J, Playfer J: Dementia with Lewy bodies. Lancet Neurol. 2004, 3 (1): 19-28. 10.1016/S1474-4422(03)00619-7.CrossRefPubMed McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Machado JC, O’Brien J, Playfer J: Dementia with Lewy bodies. Lancet Neurol. 2004, 3 (1): 19-28. 10.1016/S1474-4422(03)00619-7.CrossRefPubMed
22.
go back to reference Baskys A: Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004, 65 (Suppl 11): 16-22.PubMed Baskys A: Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004, 65 (Suppl 11): 16-22.PubMed
23.
go back to reference Shim YS, Roe CM, Buckles VD, Morris JC: Clinicopathologic study of Alzheimer’s disease: Alzheimer mimics. J Alzheimers Dis. 2013, 35 (4): 799-811.PubMedPubMedCentral Shim YS, Roe CM, Buckles VD, Morris JC: Clinicopathologic study of Alzheimer’s disease: Alzheimer mimics. J Alzheimers Dis. 2013, 35 (4): 799-811.PubMedPubMedCentral
24.
go back to reference Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA: The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006, 20 (4): 210-216. 10.1097/01.wad.0000213865.09806.92.CrossRefPubMed Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA: The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006, 20 (4): 210-216. 10.1097/01.wad.0000213865.09806.92.CrossRefPubMed
25.
go back to reference Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991, 41 (4): 479-486. 10.1212/WNL.41.4.479.CrossRefPubMed Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991, 41 (4): 479-486. 10.1212/WNL.41.4.479.CrossRefPubMed
26.
go back to reference McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984, 34 (7): 939-944. 10.1212/WNL.34.7.939.CrossRefPubMed McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984, 34 (7): 939-944. 10.1212/WNL.34.7.939.CrossRefPubMed
27.
go back to reference Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82 (4): 239-259. 10.1007/BF00308809.CrossRefPubMed Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82 (4): 239-259. 10.1007/BF00308809.CrossRefPubMed
28.
go back to reference Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6.CrossRefPubMed
29.
go back to reference Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S: Measurement of functional activities in older adults in the community. J Gerontol. 1982, 37 (3): 323-329. 10.1093/geronj/37.3.323.CrossRefPubMed Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S: Measurement of functional activities in older adults in the community. J Gerontol. 1982, 37 (3): 323-329. 10.1093/geronj/37.3.323.CrossRefPubMed
30.
go back to reference Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994, 44 (12): 2308-2314. 10.1212/WNL.44.12.2308.CrossRefPubMed Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994, 44 (12): 2308-2314. 10.1212/WNL.44.12.2308.CrossRefPubMed
31.
go back to reference Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982, 17 (1): 37-49. 10.1016/0022-3956(82)90033-4.CrossRefPubMed Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982, 17 (1): 37-49. 10.1016/0022-3956(82)90033-4.CrossRefPubMed
32.
go back to reference Di Napoli M: Benefits of statins in cerebrovascular disease. Curr Opin Investig Drugs. 2004, 5 (3): 295-305.PubMed Di Napoli M: Benefits of statins in cerebrovascular disease. Curr Opin Investig Drugs. 2004, 5 (3): 295-305.PubMed
33.
go back to reference Mendez MF: Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009, 24: 168-178.CrossRefPubMed Mendez MF: Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci. 2009, 24: 168-178.CrossRefPubMed
34.
go back to reference Hodges JR: Hope abandoned: memantine therapy in frontotemporal dementia. Lancet Neurol. 2013, 12 (2): 121-123. 10.1016/S1474-4422(13)70001-2.CrossRefPubMed Hodges JR: Hope abandoned: memantine therapy in frontotemporal dementia. Lancet Neurol. 2013, 12 (2): 121-123. 10.1016/S1474-4422(13)70001-2.CrossRefPubMed
36.
go back to reference Rolinski M, Fox C, Maidment I, McShane R: Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012, 3: CD006504 Rolinski M, Fox C, Maidment I, McShane R: Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012, 3: CD006504
37.
go back to reference SAS Institute Inc: Base SAS® 9.3 Procedures Guide. 2011, Cary, NC: SAS Institute Inc SAS Institute Inc: Base SAS® 9.3 Procedures Guide. 2011, Cary, NC: SAS Institute Inc
38.
go back to reference Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD: Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011, 26 (4): 627-645.PubMed Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD: Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011, 26 (4): 627-645.PubMed
39.
go back to reference Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y: Diagnostic accuracy of 18 F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012, 66 (2): 185-198. 10.1111/j.1742-1241.2011.02845.x.CrossRefPubMed Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y: Diagnostic accuracy of 18 F-FDG and 11C-PIB-PET for prediction of short-term conversion to Alzheimer’s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012, 66 (2): 185-198. 10.1111/j.1742-1241.2011.02845.x.CrossRefPubMed
40.
go back to reference Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA, for the AV45-A17 Study Group: Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013, 27 (1): 4-15. 10.1097/WAD.0b013e318279d02a.CrossRefPubMed Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA, for the AV45-A17 Study Group: Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013, 27 (1): 4-15. 10.1097/WAD.0b013e318279d02a.CrossRefPubMed
41.
go back to reference Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, Hock C, Kunz M, Kuhlmann J, Reininger C, Blankenburg M: Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012, 33 (6): 416-422. 10.1159/000339367.CrossRefPubMed Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, Hock C, Kunz M, Kuhlmann J, Reininger C, Blankenburg M: Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012, 33 (6): 416-422. 10.1159/000339367.CrossRefPubMed
Metadata
Title
Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS database
Authors
Joseph E Gaugler
Haya Ascher-Svanum
David L Roth
Tolulope Fafowora
Andrew Siderowf
Thomas G Beach
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2013
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/1471-2318-13-137

Other articles of this Issue 1/2013

BMC Geriatrics 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.